MedicineBiology

Yuxiang Lin, Zening Huang, Ziyan Lin, Yating Lin, Jinsheng Song, Ling Luo, J. Chi, Ye Zheng, Youxin Gao, Junjie Lin, Xinyu Li, Chenyu Liang, Lei Zhang, Xinkang Wang, Yuqin Sun, Rongshan Yu, Qiyue Chen, Mengsha Tong

2026.2.13Genome Medicine

DOI: 10.1186/s13073-026-01604-2

tlooto Summary

TiRank offers a phenotype-guided, cross-modal strategy to prioritize clinically relevant spatial niches by coupling an REO-based representation with transfer learning from bulk clinical cohorts, and enables clinically supervised niche prioritization without requiring large, matched single-cell or spatial clinical cohorts.

Abstract

Tumor microenvironment (TME) plays a crucial role in cancer progression, metastasis, and treatment response. Recent advances in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have provided valuable insights into the cellular diversity and spatial organization of the TME. However, prioritizing clinically relevant cellular subpopulations in spatial contexts using high-dimensional and sparse data remains a challenge. We introduce TiRank, a novel framework designed to prioritize clinically relevant spatial niches. TiRank incorporates a relative expression ordering (REO)-transformation module to mitigate systematic biases across modalities and utilizes a multitask transfer learning framework to align scRNA-seq, ST, and bulk transcriptomes into a unified embedding space. We benchmarked TiRank using multiple public datasets and pan-cancer clinical cohorts, demonstrating its capability to identify phenotypic cell subpopulations and spatial niches. By integrating scRNA-seq, ST, and bulk transcriptomics with clinical phenotypes, TiRank demonstrates high accuracy in identifying drug-sensitive cells and clinically relevant spatial niches across various cancer types. As a case study, we applied TiRank to gastric cancer (GC) to prioritize spatial niches associated with patient outcomes. In our clinical cohort, TiRank successfully revealed a distinct spatial niche at the tumor boundary, characterized by an enrichment of cancer-associated fibroblasts (CAFs). This niche was associated with the efficacy of different treatment regimens. To validate this finding, we further performed multiplex protein imaging on an independent cohort to confirm the spatial distribution of the CAFs-enriched barrier. Moreover, this barrier, termed Fibro-Bar, was strongly correlated with treatment response to neo-adjuvant chemoimmunotherapy. To improve accessibility, we developed TiRank as an open-source tool with an interactive graphical user interface for both researchers and clinicians. TiRank offers a phenotype-guided, cross-modal strategy to prioritize clinically relevant spatial niches by coupling an REO-based representation with transfer learning from bulk clinical cohorts. This design enables clinically supervised niche prioritization without requiring large, matched single-cell or spatial clinical cohorts, advancing biomarker discovery and supporting precision oncology.

Citation format

LIN, Yuxiang, et al. Tirank prioritizes phenotypic niches in tumor microenvironment for clinical biomarker discovery. Genome Medicine, 2026, 18(1): 23.